Kang An, Yali Han, Chengjuan Luo, Wenting Hu, Juan Qian
{"title":"小儿重症监护病房重症非hiv相关性肺囊虫肺炎的临床特征和结局","authors":"Kang An, Yali Han, Chengjuan Luo, Wenting Hu, Juan Qian","doi":"10.1002/ppul.71217","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pneumocystis jirovecii is an important cause of opportunistic pneumonia in immunocompromised patients. The aim of this study was to investigate the clinical, laboratory, imaging characteristics, and prognosis of Pneumocystis jirovecii pneumonia (PJP) in immunocompromised non-HIV pediatric patients.</p><p><strong>Methods: </strong>This was a retrospective, observational study. Continuous variables were expressed as median and interquartile range and evaluated by Mann Whitney U test. Risk factors associated with 90-day all-cause mortality were evaluated by a logistic regression model.</p><p><strong>Results: </strong>Twenty-two patients (55%) had previously undergone transplantation; 19 (47.5%) liver transplants and 3 (7.5%) allogeneic hematopoietic stem cell transplants. The remaining 18 patients included 12 with acute lymphoblastic leukemia (30%) with 6 others (15%). Eight patients (20%) presented with shock on admission. Fifteen patients (37.5%) had received PJP prophylaxis before PJP onset. The median duration of hospitalization was 26 (20-34) days with a median saty of 18 (11-25) days in the pediatric intensive care unit (PICU). The 30 day all-cause mortality was 12.5% (5/40). The 90 day all-cause mortality was 22.5% (9/40). Compared with survivors, non-survivors had a significantly higher Pediatric Sequential Organ Failure Assessment Score (pSOFA) (11 vs 4; p < 0.01) and lower SpO2 at presentation (88% vs 90%; p = 0.046). Multivariate analysis showed that the pSOFA [95% CI 1.983 (1.183-3.325); p = 0.009)] was the only significant risk factor for mortality. Although there was no statistically significant difference, patients who received adjunctive glucocorticoid therapy had a shorter duration of mechanical ventilation compared to those who did not (12 vs. 15 days; p = 0.26).</p><p><strong>Conclusions: </strong>PJP remains life-threatening in immunocompromised pediatric patients. pSOFA was a significant risk factor for mortality.</p>","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":"60 8","pages":"e71217"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics and Outcomes of Severe Non-HIV Related Pneumocystis jirovecii Pneumonia in the Pediatric Intensive Care Unit.\",\"authors\":\"Kang An, Yali Han, Chengjuan Luo, Wenting Hu, Juan Qian\",\"doi\":\"10.1002/ppul.71217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pneumocystis jirovecii is an important cause of opportunistic pneumonia in immunocompromised patients. The aim of this study was to investigate the clinical, laboratory, imaging characteristics, and prognosis of Pneumocystis jirovecii pneumonia (PJP) in immunocompromised non-HIV pediatric patients.</p><p><strong>Methods: </strong>This was a retrospective, observational study. Continuous variables were expressed as median and interquartile range and evaluated by Mann Whitney U test. Risk factors associated with 90-day all-cause mortality were evaluated by a logistic regression model.</p><p><strong>Results: </strong>Twenty-two patients (55%) had previously undergone transplantation; 19 (47.5%) liver transplants and 3 (7.5%) allogeneic hematopoietic stem cell transplants. The remaining 18 patients included 12 with acute lymphoblastic leukemia (30%) with 6 others (15%). Eight patients (20%) presented with shock on admission. Fifteen patients (37.5%) had received PJP prophylaxis before PJP onset. The median duration of hospitalization was 26 (20-34) days with a median saty of 18 (11-25) days in the pediatric intensive care unit (PICU). The 30 day all-cause mortality was 12.5% (5/40). The 90 day all-cause mortality was 22.5% (9/40). Compared with survivors, non-survivors had a significantly higher Pediatric Sequential Organ Failure Assessment Score (pSOFA) (11 vs 4; p < 0.01) and lower SpO2 at presentation (88% vs 90%; p = 0.046). Multivariate analysis showed that the pSOFA [95% CI 1.983 (1.183-3.325); p = 0.009)] was the only significant risk factor for mortality. Although there was no statistically significant difference, patients who received adjunctive glucocorticoid therapy had a shorter duration of mechanical ventilation compared to those who did not (12 vs. 15 days; p = 0.26).</p><p><strong>Conclusions: </strong>PJP remains life-threatening in immunocompromised pediatric patients. pSOFA was a significant risk factor for mortality.</p>\",\"PeriodicalId\":19932,\"journal\":{\"name\":\"Pediatric Pulmonology\",\"volume\":\"60 8\",\"pages\":\"e71217\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Pulmonology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ppul.71217\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.71217","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
Clinical Characteristics and Outcomes of Severe Non-HIV Related Pneumocystis jirovecii Pneumonia in the Pediatric Intensive Care Unit.
Background: Pneumocystis jirovecii is an important cause of opportunistic pneumonia in immunocompromised patients. The aim of this study was to investigate the clinical, laboratory, imaging characteristics, and prognosis of Pneumocystis jirovecii pneumonia (PJP) in immunocompromised non-HIV pediatric patients.
Methods: This was a retrospective, observational study. Continuous variables were expressed as median and interquartile range and evaluated by Mann Whitney U test. Risk factors associated with 90-day all-cause mortality were evaluated by a logistic regression model.
Results: Twenty-two patients (55%) had previously undergone transplantation; 19 (47.5%) liver transplants and 3 (7.5%) allogeneic hematopoietic stem cell transplants. The remaining 18 patients included 12 with acute lymphoblastic leukemia (30%) with 6 others (15%). Eight patients (20%) presented with shock on admission. Fifteen patients (37.5%) had received PJP prophylaxis before PJP onset. The median duration of hospitalization was 26 (20-34) days with a median saty of 18 (11-25) days in the pediatric intensive care unit (PICU). The 30 day all-cause mortality was 12.5% (5/40). The 90 day all-cause mortality was 22.5% (9/40). Compared with survivors, non-survivors had a significantly higher Pediatric Sequential Organ Failure Assessment Score (pSOFA) (11 vs 4; p < 0.01) and lower SpO2 at presentation (88% vs 90%; p = 0.046). Multivariate analysis showed that the pSOFA [95% CI 1.983 (1.183-3.325); p = 0.009)] was the only significant risk factor for mortality. Although there was no statistically significant difference, patients who received adjunctive glucocorticoid therapy had a shorter duration of mechanical ventilation compared to those who did not (12 vs. 15 days; p = 0.26).
Conclusions: PJP remains life-threatening in immunocompromised pediatric patients. pSOFA was a significant risk factor for mortality.
期刊介绍:
Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases.
PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.